Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000638088 | SCV000759568 | benign | Nephronophthisis | 2024-01-31 | criteria provided, single submitter | clinical testing | |
| Eurofins Ntd Llc |
RCV000728199 | SCV000855743 | uncertain significance | not provided | 2018-06-15 | criteria provided, single submitter | clinical testing | |
| Revvity Omics, |
RCV003133423 | SCV003815644 | uncertain significance | Infantile nephronophthisis | 2022-04-20 | criteria provided, single submitter | clinical testing | |
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV003330857 | SCV004037832 | uncertain significance | not specified | 2023-08-31 | criteria provided, single submitter | clinical testing | Variant summary: INVS c.3182dupA (p.Asn1061LysfsX20) causes a frameshift which results in an extension of the protein. The variant allele was found at a frequency of 0.00013 in 250686 control chromosomes. c.3182dupA has been reported in the literature in a patient with Bardet-Biedl syndrome and a patient with kidney and urinary tract abnormalities without evidence for causality (Nicolaou_2016 and Redin_2012). These reports do not provide unequivocal conclusions about association of the variant with Infantile Nephronophthisis. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 26489027, 22773737). Three submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 and classified as VUS (n=2) and likely benign (n=1). Based on the evidence outlined above, the variant was classified as uncertain significance. |